EcoR1 Capital GPCR Position
Active16-Fund ConvergenceEcoR1 Capital initiated a new position in Structure Therapeutics Inc. (GPCR) in Q4 2025, holding $23.3M worth of shares across 334,380 shares.
GPCR is a convergence signal: 16 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Aleniglipron or Placebo in 106 days (Jul 31, 2026), making the timing of EcoR1's position particularly relevant.
About Structure Therapeutics Inc.
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Full company profile →Short Interest
9.9%
6.5 days to cover
Frequently Asked Questions
Does EcoR1 Capital own GPCR?
Yes. As of Q4 2025, EcoR1 Capital holds 334,380 shares of Structure Therapeutics Inc. (GPCR) valued at $23.3M. This data comes from their SEC 13F filing.
How many hedge funds own GPCR?
16 specialist biotech hedge funds currently hold GPCR, including Avoro Capital Advisors, Deep Track Capital, BVF Partners and 12 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did EcoR1 Capital first buy GPCR?
EcoR1 Capital's position in GPCR was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is EcoR1 Capital's GPCR position increasing or decreasing?
EcoR1 Capital initiated a new position in GPCR in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
GPCRCompany Page →
All fund holders, insider trades, catalysts, and cash runway
EcoR1 CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →